ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: However, it may be possible that imatinib exerts different effects between proliferating cells and differentiating cells in CML, meaning that imatinib exerts growth-inhibitory effects against proliferating cells, as exemplified in 32D/p210BCR-ABL cells, and differentiation-suppressive effects against differentiating cells, as exemplified in Tet-regulatable p210BCR-ABL-expressing 32D/TetOff-p210 cells.